[OH-].[Mg+2:2].[OH-].[C:4]([O-:13])(=[O:12])[C:5]1[C:6](=[CH:8][CH:9]=[CH:10][CH:11]=1)[OH:7].[Na+]>O>[C:4]([O-:13])(=[O:12])[C:5]1[C:6](=[CH:8][CH:9]=[CH:10][CH:11]=1)[OH:7].[Mg+2:2].[C:4]([O-:13])(=[O:12])[C:5]1[C:6](=[CH:8][CH:9]=[CH:10][CH:11]=1)[OH:7]Magnesium hydroxide (0.0116 g; 0.0002 mol) is dissolved in 100 ml of water by gradual stirring. 0.03 g (0.0002 mols) of sodium salicylate is added to the solution to yield a magnesium salicylate molar ratio of 1:1. The resulting solution added to a 300 ml solution containing 0.225 g of membrane translocating peptide. The resulting solution is stirred at 4° Celsius for 12 hours and lyophilized to a volume of 200 ml. The solution is left to precipitate an inventive complex. The complex is filtered, washed with ether and purified commensurate with pharmaceutical purity requirements.